Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anixa Biosciences Inc (ANIX)

Anixa Biosciences Inc (ANIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 133,972
  • Shares Outstanding, K 32,917
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,550 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.30

Options Overview Details

View History
  • Implied Volatility 189.14% ( -82.39%)
  • Historical Volatility 96.44%
  • IV Percentile 41%
  • IV Rank 19.66%
  • IV High 637.62% on 04/08/25
  • IV Low 79.42% on 05/29/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 18
  • Volume Avg (30-Day) 401
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 7,178
  • Open Int (30-Day) 6,929

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 10/31/25
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.09
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.35 +21.19%
on 10/07/25
4.98 -18.47%
on 10/09/25
+0.81 (+24.92%)
since 10/06/25
3-Month
2.90 +40.00%
on 08/11/25
4.98 -18.47%
on 10/09/25
+0.96 (+30.97%)
since 08/06/25
52-Week
2.07 +96.14%
on 01/14/25
4.98 -18.47%
on 10/09/25
+0.61 (+17.68%)
since 11/06/24

Most Recent Stories

More News
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

Completion of key step in IND transfer for upcoming Phase 2 breast cancer vaccine clinical trial

ANIX : 4.06 (-0.25%)
Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference

SAN JOSE, Calif. , Oct. 23, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 4.06 (-0.25%)
Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

Expands global intellectual property coverage in markets with high breast cancer incidence

ANIX : 4.06 (-0.25%)
Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial

Final Clinical Visit Marks Major Milestone in First-in-Human Evaluation of Breast Cancer Vaccine

ANIX : 4.06 (-0.25%)
Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

Phase 1 Data Highlights Potential of First-in-Class Vaccine to Transform Breast Cancer Treatment and Prevention

ANIX : 4.06 (-0.25%)
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals

/CNW/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August 2025[1] signaled the recent wave of regulatory...

ONCY : 1.0100 (unch)
ANIX : 4.06 (-0.25%)
ICCM : 0.6927 (-2.44%)
REGN : 646.87 (+0.42%)
IBRX : 2.12 (-1.40%)
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals

Issued on behalf of Oncolytics Biotech Inc.

ONCY : 1.0100 (unch)
ANIX : 4.06 (-0.25%)
ICCM : 0.6927 (-2.44%)
REGN : 646.87 (+0.42%)
IBRX : 2.12 (-1.40%)
3 Under-the-Radar Biotechs Under $5 That Could Soar 200%

3 biotech stocks under $5 with cancer, obesity, and psychedelic therapies offer speculative investors high-risk, high-reward potential: HOTH, SILO, and ANIX.

ANIX : 4.06 (-0.25%)
HOTH : 1.2800 (-2.29%)
SILO : 0.4932 (-2.70%)
Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Continue to observe a positive safety profile—no dose limiting toxicities, cytokine release syndrome or immune effector cell-associated neurotoxicity

ANIX : 4.06 (-0.25%)
Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

SAN JOSE, Calif. , Sept. 2, 2025 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention...

ANIX : 4.06 (-0.25%)

Business Summary

Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.

See More

Key Turning Points

3rd Resistance Point 4.16
2nd Resistance Point 4.12
1st Resistance Point 4.09
Last Price 4.06
1st Support Level 4.02
2nd Support Level 3.98
3rd Support Level 3.95

See More

52-Week High 4.98
Last Price 4.06
Fibonacci 61.8% 3.87
Fibonacci 50% 3.53
Fibonacci 38.2% 3.18
52-Week Low 2.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar